Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Murdo Gordon
Pharma
In quarterly earnings report, Amgen shows off Lumakras launch
Lumakras sales came in at $36 million for the third quarter, a positive start for Amgen's first-in-class lung cancer treatment.
Kevin Dunleavy
Nov 3, 2021 11:50am
Amgen scores Otezla patent win, nabbing protection until 2028
Sep 21, 2021 10:00am
Early days, but Lumakras expectations are high, Amgen execs say
Aug 5, 2021 9:50am
Amgen contends IRS' bid for $3.6B in back taxes
Aug 4, 2021 8:25am
Otezla's pressures reflected in Amgen's 1st quarter earnings
Apr 28, 2021 9:58am
Amgen cuts 500 U.S. jobs, mostly sales reps
Feb 3, 2021 2:26pm